SEC Form 4 · accession 0001181431-15-002198
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James S Scibetta
Officer — SVP, Chief Financial Officer
Period of report
Feb 6, 2015
Accepted (ET)
Feb 9, 2015 · 9:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF7 | Feb 6, 2015 | M | 15,000 | $1.61 | A | 20,230 | D | |
| Common StockF2 | Feb 6, 2015 | S | 4,293 | $110.17 | D | 15,937 | D | |
| Common StockF3 | Feb 6, 2015 | S | 5,904 | $111.11 | D | 10,033 | D | |
| Common StockF4 | Feb 6, 2015 | S | 3,103 | $111.98 | D | 6,930 | D | |
| Common StockF5 | Feb 6, 2015 | S | 1,700 | $112.91 | D | 5,230 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $1.61 | Feb 6, 2015 | M | 15,000 | D | — | Sep 2, 2020 | Common Stock | 15,000 | 38,250 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.58 to $110.57, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.59 to $111.58, inclusive.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.59 to $112.58, inclusive.
- F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $112.63 to $113.17, inclusive.
- F6The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.
- F7Includes 230 shares of common stock acquired under the issuer's employee stock purchase plan in December 2014.